Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Executive VP Global Operations | May 18, 2019 | May 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 18, 2019 · Filed May 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 33,588.727 |
Last balance in matching sequence
After 2019-05-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-05-18 · Exercise / conversion · Acquired 30,875 · Balance 49,658.727 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2019-05-20 · Sale · Disposed 16,070 · Balance 33,588.727 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-18 · Exercise / conversion · Disposed 30,875 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on May 18, 2017 and vested on May 18, 2019. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5: Restricted share units were granted on May 18, 2017 and vested on May 18, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2019 Filed May 21, 2019 10:38 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 16,070 | $11.42 | $183,519.40 |
DisclosureSEC source: 0001209191-19-031609 · doc4.xml · nonDerivative · entry 2 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,588.727 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| May 18, 2019 Filed May 21, 2019 10:38 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 30,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031609 · doc4.xml · derivative · entry 3 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on May 18, 2017 and vested on May 18, 2019. F5 · derivative.expiration_date: Restricted share units were granted on May 18, 2017 and vested on May 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 18, 2019 Filed May 21, 2019 10:38 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 30,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-031609 · doc4.xml · nonDerivative · entry 1 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,658.727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 16, 2019 Filed May 20, 2019 11:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031213 · doc4.xml · derivative · entry 3 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 12, 2019 pursuant to the satisfaction of performance criteria and vested on May 16, 2019. F6 · derivative.expiration_date: Restricted share units were granted on February 12, 2019 pursuant to the satisfaction of performance criteria and vested on May 16, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 16, 2019 Filed May 20, 2019 11:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 629 | $11.76 | $7,397.04 |
DisclosureSEC source: 0001209191-19-031213 · doc4.xml · nonDerivative · entry 2 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,783.727 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| May 16, 2019 Filed May 20, 2019 11:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-031213 · doc4.xml · nonDerivative · entry 1 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,412.727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The Ordinary Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 74,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017228 · doc4.xml · derivative · entry 1 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,626 Underlying: Ordinary Shares · 74,626 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 24,875 vesting on each of March 4, 2021 and March 4, 2022 and 24,876 vesting on March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 24,875 vesting on each of March 4, 2021 and March 4, 2022 and 24,876 vesting on March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 9,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010835 · doc4.xml · derivative · entry 3 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,560 Underlying: Ordinary Shares · 9,280 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 9,280 vesting on each of February 14, 2019, February 14, 2020 and February 14, 2021. F6 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 9,280 vesting on each of February 14, 2019, February 14, 2020 and February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 3,192 | $17.67 | $56,399.45 |
DisclosureSEC source: 0001209191-19-010835 · doc4.xml · nonDerivative · entry 2 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,208.727 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.675, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 9,280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-010835 · doc4.xml · nonDerivative · entry 1 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400.727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 12:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 5,041 | $17.88 | $90,107.88 |
DisclosureSEC source: 0001209191-19-009989 · doc4.xml · nonDerivative · entry 2 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,120.727 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the performance share units. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $17.88, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 12:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 1,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009989 · doc4.xml · derivative · entry 3 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,204 Underlying: Ordinary Shares · 1,204 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time based vesting and will vest on May 16, 2019. F7 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time based vesting and will vest on May 16, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 12:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 14,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-009989 · doc4.xml · nonDerivative · entry 1 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,161.727 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The Ordinary Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 62,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009181 · doc4.xml · derivative · entry 2 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,690 Underlying: Ordinary Shares · 62,690 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 20,896 vesting on each of February 9, 2020 and February 9, 2021 and 20,898 vesting on February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 20,896 vesting on each of February 9, 2020 and February 9, 2021 and 20,898 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 159,819 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009181 · doc4.xml · derivative · entry 1 de Notaristefani Carlo · CIK 0001719114 · Executive VP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,819 Underlying: Ordinary Shares · 159,819 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 53,273 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.